VRPX vs. VIRX, APM, ABVC, CNSP, GLTO, KZIA, GRI, ADIL, ALZN, and TRIB
Should you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include Viracta Therapeutics (VIRX), Aptorum Group (APM), ABVC BioPharma (ABVC), CNS Pharmaceuticals (CNSP), Galecto (GLTO), Kazia Therapeutics (KZIA), GRI Bio (GRI), Adial Pharmaceuticals (ADIL), Alzamend Neuro (ALZN), and Trinity Biotech (TRIB). These companies are all part of the "pharmaceutical products" industry.
Virpax Pharmaceuticals vs.
Viracta Therapeutics (NASDAQ:VIRX) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.
Viracta Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.
Virpax Pharmaceuticals' return on equity of -1,554.34% beat Viracta Therapeutics' return on equity.
Viracta Therapeutics received 26 more outperform votes than Virpax Pharmaceuticals when rated by MarketBeat users. Likewise, 70.73% of users gave Viracta Therapeutics an outperform vote while only 60.00% of users gave Virpax Pharmaceuticals an outperform vote.
In the previous week, Virpax Pharmaceuticals had 1 more articles in the media than Viracta Therapeutics. MarketBeat recorded 1 mentions for Virpax Pharmaceuticals and 0 mentions for Viracta Therapeutics. Viracta Therapeutics' average media sentiment score of 0.00 beat Virpax Pharmaceuticals' score of -0.55 indicating that Viracta Therapeutics is being referred to more favorably in the media.
31.4% of Viracta Therapeutics shares are held by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 10.7% of Viracta Therapeutics shares are held by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Viracta Therapeutics currently has a consensus price target of $4.05, indicating a potential upside of 2,329.51%. Virpax Pharmaceuticals has a consensus price target of $3.00, indicating a potential upside of 921.80%. Given Viracta Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viracta Therapeutics is more favorable than Virpax Pharmaceuticals.
Summary
Viracta Therapeutics beats Virpax Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Get Virpax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Virpax Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:VRPX) was last updated on 1/22/2025 by MarketBeat.com Staff
Free VRPX Stock Alerts